Hexima Limited listed its ordinary shares on ASX on 1 December 2020 under the ticker “HXL”.
CURRENT Share Price
To view Hexima’s share price, visit the ASX website by clicking the button below
Hexima (ASX:HXL) is a clinical stage, anti-infectives focused biotechnology company engaged in the research and development of plant defensin peptides for applications as human therapeutics. Our lead product candidate, pezadeftide (HXP124) applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting advanced global clinical trials testing pezadeftide for the treatment of onychomycosis. Hexima holds granted, long-life patents protecting pezadeftide in major markets globally. The Company’s patent-protected antifungal technology also has the potential to treat other localised fungal infections.
CORPORATE PRESENTATION >>
ANNUAL REPORT >>
Large and growing market opportunity with clear unmet need.
Onychomycosis affects 14% of the US population¹. The current global market for onychomycosis treatments was US$3.7 billion in 2018².
There is an unmet need of both clinicians and patients for a safe topical treatment with greater efficacy and a shorter course of treatment.
Lead compound, pezadeftide, is a novel, patent protected molecule with a unique mode of action.
Pezadeftide is a new biologic with a novel fungicidal mode of action. It rapidly penetrates the human nail to target the site of infection.
Pezadeftide has demonstrated a favourable safety profile and delivers effective and rapid antifungal treatment.
Pezadeftide promises greater efficacy than existing topical products with a shorter and more convenient treatment duration.
Advanced development program and experienced management team
Pezadeftide is currently in advanced clinical trials. Hexima’s executive team encompasses a mix of established corporate, clinical research, and operational executives – with a track record of executing on product development programs and delivering value.
9 Dec 2021: Wilsons Initiation of Coverage
20 May 2022: Morgans Research Report
1 Jun 2022: Wilsons Research Report
Current Financial Reports
Latest ASX Announcements
Hexima’s head office is located in the grounds of La Trobe University, Bundoora. Please note that visits are by appointment only.
Level 4, LIMS2
La Trobe University VIC 3086
P: +61 3 9479 1210
ASX code: HXL
Fiscal year end: 30 June
For more information about your Hexima Limited security holding please contact:
Link Market Services
Level 12, 680 George Street
Sydney NSW 2000
Locked Bag A14
Sydney South NSW 1235
P: +61 1300 554 474 (toll free within Australia)
F: +61 2 9287 0303
When you visit the Link Investor Centre, you will need your Security Reference Number (SRN) or Holder Identification Number (HIN) to verify your identity. Your SRN/HIN is available on your holding/transaction and distribution statements.